% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • mikeylikesit33_99 mikeylikesit33_99 Aug 27, 2013 10:46 AM Flag

    Janney summary

    We are reiterating our Buy rating and raising our fair value on the shares of QCOR from $65 to $90 based on increased expectations for Acthar Rx growth in the recently launched rheumatology (RA) segment and by assigning a higher P/Sales multiple on the various indications for Acthar based on the significant rates of growth that we have seen to date, and which we believe could continue going forward. Our new $90 FV still represents a forward P/E of ~12x 2014 EPS, which remains a discount to the specialty pharma group at 14x-16x, which we believe accounts for the particular risks within the QCOR story. As the new RA launch continues to build steam in 2014-2015 we believe that the size of the under-served markets in RA could come to dwarf the Multiple Sclerosis (MS) opportunity and even surpass the Nephrotic Syndrome (NS) opportunity in the outer years. We are reiterating our Buy rating and raising our FV to $90 from $65.
    Rheumatology continues gathering speed. Having launched their pilot Rheumatology program in 3Q12, QCOR has continued to see Rheumatology segment as the main growth driver for new Rx's of Acthar gel. After deciding late in 3Q12 to expand the program from the initial 10 pilot reps to 55 reps, QCOR saw 1Q13 bring in 140-150 new paid Rxs with that expanding to over 300+ new paid Rx in the first full quarter of sales in 2Q13, making RA the fastest growth segment for Acthar. With each new Rx averaging ~5 vials, we project that this segment will continue its high growth through our forecast period. See table later in this report for our detailed breakdown of Acthar Rx's by indication through 2016.
    · Substantial Rheumatology patient population. Though QCOR's usual modus operandi is orphan populations (2K-5K), the size of the potential treatment populations for Acthar in Systematic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PA), three approved indications within the Rheumatology segment, is significant. QCOR estimat

    SortNewest  |  Oldest  |  Most Replied Expand all replies